<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166944</url>
  </required_header>
  <id_info>
    <org_study_id>201307022</org_study_id>
    <nct_id>NCT02166944</nct_id>
  </id_info>
  <brief_title>Tamoxifen Treatment in Patients With Motor Neuron Disease</brief_title>
  <official_title>The Study of Tamoxifen Treatment in Patients With Motor Neuron Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University Shuang Ho Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Medical University Shuang Ho Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to survey the effect of Tamoxifen in motor neuron disease (MND)
      patients, amyotrophic lateral sclerosis (ALS) with regular riluzole usage. TDP-43 is related
      to ALS. Increased the ubiquitinated or phosphorylated TDP-43 can cause animal model of ALS,
      and TDP43 can be degraded either by proteasome or autophagy pathway system. Autophagy pathway
      can be activated by mTOR inhibition, resulting in ameliorating TDP-43 accumulation and rescue
      in motor function in animal model. Tamoxifen had shown ability of enhance both proteasome and
      autophagy pathway, therefore the investigators assume that Tamoxifen probably can ameliorate
      TDP-43 accumulation and inclusion body formation in ALS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will assess the ALSFR-s in ALS patients at start, 1, 3, 6 and 12 months and
      correlate the score to the neurological outcome of the patients with and without tamoxifen
      treatment at dose of 40mg daily for one year.

      The study will be able to prove the investigators hypothesis: Tamoxifen, a protease and
      autophagy enhancer, has synergic effect with riluzole in ALS patients to slowing the
      progression of neurological dysfunction, and respiratory insufficiency.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Amyotrophic Lateral Sclerosis Functional Ration Scales (ALSFRS) at 1, 3, 6,12 months</measure>
    <time_frame>Baseline, month 1, 3, 6, 12</time_frame>
    <description>Amyotrophic Lateral Sclerosis Functional Ration Scales (ALSFRS) measured by a neurologist</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in pulmonary function test at 1, 3, 6,12 months</measure>
    <time_frame>baseline, month 1, 3, 6, 12</time_frame>
    <description>Expiratory reserve volume (ERV) Forced vital capacity (FVC) Forced expiratory volume (FEV) Forced expiratory flow 25% to 75% Functional residual capacity (FRC) Maximum voluntary ventilation (MVV)
Residual volume (RV)
Peak expiratory flow (PEF).
Slow vital capacity (SVC)
Total lung capacity (TLC)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline in blood TDP43 related biomarkers at 1, 3, 6,12 months</measure>
    <time_frame>baseline, month 1, 3, 6, 12</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>ALS Functional Ration Scale</condition>
  <condition>TAR-DNA-binding Protein-43</condition>
  <condition>Tamoxifen</condition>
  <condition>mTOR</condition>
  <arm_group>
    <arm_group_label>tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tamoxifen 40 mg daily for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen 40 mg daily for one year</intervention_name>
    <description>both arms with riluzole daily</description>
    <arm_group_label>tamoxifen</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosed and confirmed ALS patients, with regular follow up and oral form
             riluzole at National Taiwan University or Shuang- Ho Hospital for more than 6 months.

          2. Age â‰§20 years old

        Exclusion Criteria:

          1. Patients who had already ventilator dependent, not regular followed up for more than 6
             months or against medical advice, refuse to follow up at neurology department will be
             excluded in this study.

          2. Patients with now or previous usage of Tamoxifen

          3. Patients with any contraindications of Tamoxifen usage

          4. Patients with other internal medicine illiness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaur-Jong Hu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shung Ho Hospital, Taipei Meidcal University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Po-Chih Chen, M.D.</last_name>
    <phone>886-2-22490088</phone>
    <phone_ext>8112</phone_ext>
    <email>euphemus2003@msn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chaur-Jong Hu, M.D.</last_name>
    <phone>886-2-22490088</phone>
    <phone_ext>8112</phone_ext>
    <email>chaurjongh@tmu.edu.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Po-Chih Chen</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Po-Chih Chen, M.D.</last_name>
      <phone>886-2-22490088</phone>
      <phone_ext>8112</phone_ext>
      <email>euphemus2003@msn.com</email>
    </contact>
    <contact_backup>
      <last_name>Chaur-Jong Hu, M.D.</last_name>
      <phone>886-2-22490088</phone>
      <phone_ext>8112</phone_ext>
      <email>chaurjongh@tmu.edu.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Chaur-Jong Hu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <last_update_submitted>June 16, 2014</last_update_submitted>
  <last_update_submitted_qc>June 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <keyword>ALS functional ration scale</keyword>
  <keyword>TAR-DNA-binding protein-43</keyword>
  <keyword>tamoxifen</keyword>
  <keyword>mTOR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

